Celltrion's Remsima SC breaks 20% market share in Europe

South Korea's biopharmaceutical company Celltrion Inc. said on Wednesday that its subcutaneous autoimmune disease treatment Remsima SC has surpassed a 20% market share in Europe during the first quarter of this year.

Launched in 2020 as a subcutaneous formulation of its blockbuster drug Remsima, Remsima SC offers patients a convenient alternative to the previous intravenous version.

The new formulation can be self-administered every two weeks in 10 seconds, compared to the hospital-based administration required by the IV version.

According to Celltrion and market research firm IQVIA, Remsima SC achieved a 21% market share across Europe in the first quarter, marking the first time it has crossed the 20% threshold.

The company attributed the success to its country-specific sales strategies, particularly in Germany and France.

Germany, where Remsima SC commands nearly 40% of the market.

Celltrion's German subsidiary has focused on building relationships with hospitals of all sizes to secure supply channels.

France, 28% of Remsima SC's European sales, has seen the company adopt a dual formulation strategy.

This involves transitioning patients from competing products to the IV version of Remsima before switching them to Remsima SC, leveraging a tender win with major procurement organization UniHA.

Write to Jeong Min Nam at peux@hankyung.com